Investor Presentaiton

Biological Assets Based on track record, our biological assets are sold within the same year and converted into cash or recorded as account receivables RMB'000 FY2017 FY2018 FY2019 FY2020# 6M2021#* Revenue 49,500 61,708 99,490 107,741 111,176 Cost of Sales (44,640) (55,418) (88,468) (95,639) (96,342) Gain arising from changes in fair value less costs to sell of biological assets Adjusted Gross Profit** 39,712 53,615 80,697 89,517 (90,814) 44,572 59,905 91,719 101,618 105,648 Notes: FY refers to financial year ended 31 December #Unaudited financial results * Six months ended 31 December 2021 with respect to the continuing operations of the Group, being the kiwifruit business ** * Adjusted to include the gain arising from changes in fair value less costs to sell of biological assets, and the corresponding impact to cost of sales 23 23

View entire presentation